Drug Trial Radar · NCT00304031
Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Last checked: Nov 20, 2026Latest source record: Jun 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,173
Actual
Start
Jan 2006
Primary completion
Feb 2011
Study completion Dec 2016
Sponsor
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); European Organisation for Research and Treatment of Cancer - EORTC; NRG Oncology
- First posted
- Mar 17, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known which schedule of temozolomide when given together with radiation therapy is more effective in treating glioblastoma or gliosarcoma. PURPOSE: This randomized phase III trial is studying two different schedules of temozolomide to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed glioblastoma or gliosarcoma.
Conditions
- Brain and Central Nervous System Tumors
Interventions
Concurrent temozolomideDrug
Daily oral temozolomide (75 mg/m2) up to 49 doses.
Concurrent radiation therapyRadiation
60 Gy in 2 Gy fractions
100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycleDrug
Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycleDrug
Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Overall Survival TimeTime frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
Locations
351 sites in 2 countries. Site status is shown where the registry gives one.
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska
Arizona Oncology Services Foundation
Phoenix, Arizona
Mayo Clinic Scottsdale
Scottsdale, Arizona
Arizona Oncology - Tucson
Tucson, Arizona
Auburn Radiation Oncology
Auburn, California
Providence Saint Joseph Medical Center - Burbank
Burbank, California
Radiation Oncology Centers - Cameron Park
Cameron Park, California
Mercy Cancer Center at Mercy San Juan Medical Center
Carmichael, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente Medical Center - Los Angeles
Los Angeles, California
Radiation Oncology Center - Roseville
Roseville, California
Radiological Associates of Sacramento Medical Group, Incorporated
Sacramento, California
Mercy General Hospital
Sacramento, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Solano Radiation Oncology Center
Vacaville, California
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado
Poudre Valley Radiation Oncology
Fort Collins, Colorado
Yale Cancer Center
New Haven, Connecticut
Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware
CCOP - Christiana Care Health Services
Newark, Delaware
Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus
Boca Raton, Florida
University of Florida Shands Cancer Center
Gainesville, Florida
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida
Integrated Community Oncology Network at Southside Cancer Center
Jacksonville, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida
Baptist Medical Center South
Jacksonville, Florida
Integrated Community Oncology Network
Jacksonville Beach, Florida
Baptist-South Miami Regional Cancer Program
Miami, Florida
Integrated Community Oncology Network - Orange Park
Orange Park, Florida
Florida Cancer Center - Palatka
Palatka, Florida
Flagler Cancer Center
Saint Augustine, Florida
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
Tampa, Florida
Piedmont Hospital
Atlanta, Georgia
John B. Amos Cancer Center
Columbus, Georgia
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho
Northwest Community Hospital
Arlington Heights, Illinois
Rush-Copley Cancer Care Center
Aurora, Illinois
St. Joseph Medical Center
Bloomington, Illinois
Graham Hospital
Canton, Illinois
Memorial Hospital
Carthage, Illinois
Showing 40 of 351 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.